ORLANDO — AllianceRx Walgreens Pharmacy, one of the largest specialty and home delivery pharmacies in the country, is pleased to announce it has received Distinctions in Oncology, and Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). In 2022, AllianceRx Walgreens Pharmacy achieved three-year reaccreditation through ACHC for specialty pharmacy services, a prerequisite to earning these distinctions.

“We are incredibly proud to have earned these honored distinctions from ACHC. It distinguishes AllianceRx Walgreens Pharmacy as a premier specialty pharmacy partner for oncology and rare disease patients and therapies,” says Joel Wright, chief executive officer. “Our ability to meet and exceed ACHC standards, as well as receiving our certification of distinction in oncology and rare disease and orphan drugs, validates our dedication to serving these patients requiring highly specialized therapies.”

By earning these additional distinctions, AllianceRx Walgreens Pharmacy joins an elite, limited group of specialty pharmacies whom ACHC has recognized for providing exceptional and quality care to patients living with cancer and rare diseases.

The ACHC Specialty Pharmacy Accreditation with Distinction in Oncology recognizes specialty pharmacies which have demonstrated an outstanding commitment to helping ensure cancer patients receive oral cancer drugs and ancillary oral therapies in a safe, reliable, accessible and affordable environment that is integrated with their overall plan of care.

The ACHC Distinction in Rare Diseases and Orphan Drugs encompasses processes and procedures necessary to bring medications for rare diseases into market from FDA approval to patient management, employee education, and medication handling and dispensing.

Jodi Sibell, director of accreditation and document management, says the distinctions address the market and patient needs of specialization and differentiation for rare diseases and oncology. “AllianceRx Walgreens Pharmacy upholds the highest level of quality care for these specializations. I am proud of the dedication, hard work and collaboration of our team members during the accreditation process. Their commitment to this process helps provide hope and care for better tomorrows for our patients.”

The ACHC Distinctions in Oncology and Rare Diseases and Orphan Drugs are effective through September 15, 2025.